Physician profile
Dejan Micic
NPI 1356660203
$81,481.09
in general payments reported to CMS, 2019-2025
12 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $3,210 · 2021: $3,210 · 2022: $13K · 2023: $22K · 2024: $16K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $22K · Travel and Lodging: $3,802 · Food and Beverage: $990 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,020.95 |
| Consulting Fee | $21,654.56 |
| Travel and Lodging | $3,801.88 |
| Food and Beverage | $990.44 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $72,178.61 | 2020-2025 | Gattex, Entyvio |
| Ironwood Pharmaceuticals, INC | $6,582.69 | 2024-2025 | |
| Janssen Biotech, INC. | $2,252.16 | 2025 | Tremfya |
| Tersera Therapeutics LLC | $167.00 | 2023 | |
| Nestle Healthcare Nutrition INC. | $106.11 | 2023 | |
| Janssen Scientific Affairs, LLC | $67.57 | 2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.27 | 2023 | Trulance |
| Medtronic, INC. | $29.53 | 2022 | |
| Vectivbio Ag | $29.20 | 2023 | |
| Boston Scientific Corporation | $19.14 | 2025 | Overstitch Endoscopic Suturing System |
| Abbvie INC. | $14.81 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dejan Micic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.